Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. (BLLN) director Krishna Kittu Kolluri reported a series of code J “other acquisition or disposition” transactions on August 26, 2026 involving a total of 562,686 shares of Class A Common Stock held indirectly through investment funds, SPVs and trusts. The transactions reflect pro-rata, in-kind distributions among Neotribe-managed entities and various Kolluri-related trusts, all for no additional consideration, rather than open-market trading. Across these restructuring movements, aggregate net shares were neutral, and Kolluri disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
BillionToOne, Inc. (BLLN) director and Chief Technology Officer David Tsao reported an option exercise and related share sale. On 2026-08-25, he exercised 10,000 stock options for Class A Common Stock at $2.80 per share, receiving 10,000 shares, and on the same date sold 10,000 shares at $100.00 per share. Following the exercise, he held 580,000 stock options for Class A Common Stock. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026, and the options exercised were fully vested and exercisable.
BillionToOne, Inc. (BLLN) insider ten Bosch John Roderick, SVP of Laboratory Operations, reported selling 1,417 shares of Class A Common Stock on August 25, 2026 at $100.00 per share in an open market or private transaction. Following this sale, he directly holds 26,467 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. (BLLN) is the issuer of Class A common stock subject to a planned resale under Rule 144 by account holder David Tsao. The notice covers a proposed sale of 10,000 Class A shares through Fidelity Brokerage Services LLC, with an indicated aggregate value of $1,000,000.00 and reference to 42,644,388 shares outstanding as of August 25, 2026.
The shares are to be sold following a stock option exercise for cash scheduled for August 25, 2026. The notice also lists sales in the past three months by David Tsao and the DT 2021 Irrevocable Trust, for which Icontrust LLC acts as trustee and in which Tsao is an account stakeholder. The notice is signed by Emily Navaro as attorney-in-fact for David Tsao.
BillionToOne, Inc. (BLLN) is the issuer for a Form 144 notice filed on behalf of officer John R. Ten Bosch. The notice covers a proposed sale of 1,417 Class A shares to be sold through Fidelity Brokerage Services LLC. It also reports prior open-market sales of Class A shares by John R. Ten Bosch during June–August 2026, including 2,832 shares on June 15, 1,416 shares on June 29, 4,251 shares on July 13, and 1,417 shares on August 10, 2026. The securities described include Class A shares originally acquired on December 30, 2021 as pre-IPO shares received as compensation.
BillionToOne, Inc. senior vice president of laboratory operations John Roderick ten Bosch reported selling 1,417 shares of Class A Common Stock on August 10, 2026 at $92.86 per share. After this sale, he held 27,884 shares directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. director and Chief Technology Officer David Tsao exercised stock options for 10,000 shares of Class A Common Stock at $2.80 per share on August 10, 2026, then sold 10,000 shares of Class A Common Stock at $92.86 per share. Following the option exercise, he held 590,000 stock options that are fully vested and exercisable, expiring June 7, 2031. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
John R. Ten Bosch filed a notice to sell 1,417 Class A shares of BLLN, held at Fidelity Brokerage Services, with an indicated value of $131,582.62, on NASDAQ by August 10, 2026. These shares are described as Pre IPO Shares originally received as compensation.
Over the prior three months, Ten Bosch reported Class A sales of 2,832 shares for $287,363.04 on June 15, 2026, 1,416 shares for $169,920.00 on June 29, 2026, and 4,251 shares for $533,330.46 on July 13, 2026.
BLLN has a notice of proposed sale of restricted securities. An affiliated holder plans to sell 3,500 Class A shares on or after August 10, 2026 through Fidelity Brokerage Services LLC on NASDAQ. The disclosure also lists prior Class A share sales by David Tsao and the Dt 2021 Irrevocable Trust in June and July 2026, including multiple transactions of 20,000 and 3,500 shares with multi-hundred-thousand-dollar proceeds.
BillionToOne (symbol BLLN) has a Form 144/A filing indicating that insider David Tsao plans to sell 10,000 Class A shares through Fidelity Brokerage Services on 08/10/2026, following a stock option exercise. The planned sale reflects an aggregate market value of $928,600.00 on NASDAQ.
Over the prior three months, reported sales of Class A shares included 20,000 shares for $2,045,326.00 and 20,000 shares for $2,497,697.77 by David Tsao, plus 3,500 shares for $355,145.00 and 3,500 shares for $439,110.00 by the DT 2021 Irrevocable Trust.